• shareshare
  • link
  • cite
  • add
auto_awesome_motion View all 6 versions
Publication . Article . 2018

Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice

Luke W. Bonham; Luke W. Bonham; Ethan G. Geier; Natasha Z. R. Steele; Dominic Holland; Bruce L. Miller; Anders M. Dale; +5 Authors
Open Access
Published: 01 Jul 2018
Publisher: eScholarship, University of California
Country: United States
There is increasing evidence that metabolic dysfunction plays an important role in Alzheimer’s disease (AD). Brain insulin resistance and subsequent impairment of insulin and insulin-like growth factor (IGF) signaling are associated with the neurodegenerative and clinical features of AD. Nevertheless, how the brain insulin/IGF signaling system is altered in AD and the effects of these changes on AD pathobiology are not well understood. IGF binding protein 2 (IGFBP-2) is an abundant cerebral IGF signaling protein and there is early evidence suggesting it associates with AD biomarkers. We evaluated the relationship between protein levels of IGFBP-2 with cerebrospinal fluid (CSF) biomarkers and neuroimaging markers of AD progression in 300 individuals from across the AD spectrum. CSF IGFBP-2 levels were correlated with CSF tau levels and brain atrophy in non-hippocampal regions. To further explore the role of IGFBP2 in tau pathobiology, we evaluated the expression of IGFBP2 in different human and mouse brain cell types and brain tissue from two transgenic mouse models: the P301L-tau model of tauopathy and TASTPM model of AD. We observed significant differential expression of IGFBP2 in both transgenic mouse models relative to wild-type mice in cortex but not in hippocampus. In both humans and mice, IGFBP2 is most highly expressed in astrocytes. Taken together, our findings suggest that IGFBP-2 may be linked to tau pathology and provides further evidence for a relationship between metabolic dysregulation and neurodegeneration. Our results also raise the possibility that this relationship may extend beyond neurons.
Subjects by Vocabulary

Microsoft Academic Graph classification: Hippocampus Insulin medicine.medical_treatment medicine Genetically modified mouse Tauopathy medicine.disease Internal medicine medicine.medical_specialty Cerebrospinal fluid Insulin-like growth factor-binding protein biology.protein biology Endocrinology Insulin resistance Neurodegeneration

Library of Congress Subject Headings: lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry lcsh:RC321-571


IGFBP-2, Alzheimer's disease, CSF, neuroimaging, tau, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s disease, Acquired Cognitive Impairment, Neurodegenerative, Brain Disorders, Alzheimer's Disease including Alzheimer's Disease Related Dementias, Aging, Dementia, Neurosciences, 2.1 Biological and endogenous factors, Neurological, Cognitive Sciences, Psychology, Neuroscience, Original Research, IGFBP-2, Alzheimer’s disease, CSF, neuroimaging, tau, General Neuroscience, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Aetiology

63 references, page 1 of 7

Åberg D.Johansson P.Isgaard J.Wallin A.Johansson J. O.Andreasson U. (2015). Increased cerebrospinal fluid level of insulin-like growth factor-II in male patients with alzheimer’s disease. J. Alzheimers Dis. 48 637–646. 10.3233/JAD-150351 26402100 [PubMed] [DOI]

Bedse G.Di Domenico F.Serviddio G.Cassano T. (2015). Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front. Neurosci. 9:204 10.3389/fnins.2015.00204 [OpenAIRE] [DOI]

Benjamini Y.Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57 289–300. 10.2307/2346101 [OpenAIRE] [DOI]

Bennett M. L.Bennett F. C.Liddelow S. A.Ajami B.Zamanian J. L.Fernhoff N. B. (2016). New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. U.S.A. 113 E1738–E1746. 10.1073/pnas.1525528113 26884166 [OpenAIRE] [PubMed] [DOI]

Bomfim T. R.Forny-Germano L.Sa thler L. B.Brito-Moreira J.Houzel J. C.Decker H. (2012). An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers. J. Clin. Invest. 122 1339–1353. 10.1172/JCI57256 22476196 [OpenAIRE] [PubMed] [DOI]

Bonham L. W.Desikan R. S.Yokoyama J. S. (2016). The relationship between complement factor C3, APOE 𝜀4, amyloid and tau in Alzheimer’s disease. Acta Neuropathol. Commun. 4 1–7. 10.1186/s40478-016-0339-y 26727948 [OpenAIRE] [PubMed] [DOI]

Chen Y.Liang Z.Blanchard J.Dai C. L.Sun S.Lee M. H. (2013). A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD Mouse). Mol. Neurobiol. 47 711–725. 10.1007/s12035-012-8375-8375 23150171 [OpenAIRE] [PubMed] [DOI]

Craig-Schapiro R.Kuhn M.Xiong C.Pickering E. H.Liu J.Misko T. P. (2011). Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One 6:e18850. 10.1371/journal.pone.0018850 21526197 [OpenAIRE] [PubMed] [DOI]

Deng Y.Li B.Liu Y.Iqbal K.Grundke-Iqbal I.Gong C. X. (2009). Dysregulation of insulin signaling, glucose transporters, O-glcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s disease. Am. J. Pathol. 175 2089–2098. 10.2353/ajpath.2009.090157 19815707 [OpenAIRE] [PubMed] [DOI]

Desikan R. S.McEvoy L. K.Thompson W. K.Holland D.Roddey J. C.Blennow K. (2011). Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann. Neurol. 70 657–661. 10.1002/ana.22509 22002658 [OpenAIRE] [PubMed] [DOI]

Funded by
NIH| RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansion
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5K01AG049152-03
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5P50AG023501-03
NIH| Alzheimers Disease Neuroimaging Initiative
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funder: Canadian Institutes of Health Research (CIHR)
Related to Research communities